Updated cholesterol guidelines introduce important changes in cardiovascular risk assessment and lipid management that directly impact pharmacist practice. This course reviews key updates from the new ACC/AHA dyslipidemia guideline, including risk assessment tools, LDL-C targets, and evolving roles for statin and nonstatin therapies. You will be better prepared to identify practice-relevant recommendations and support evidence-based lipid management in patient care.

HOST

Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Janelle Ruisinger, PharmD, FAPhA
Associate Dean for Academic Affairs and Clinical Professor
The University of Kansas School of Pharmacy

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe key pharmacist-relevant updates in the new ACC/AHA Guideline for the Management of Dyslipidemia.
2. Differentiate risk assessment and lipid-lowering treatment considerations that may influence pharmacist recommendations under the updated guideline.

Rachel Maynard and Janelle Ruisinger have no relevant financial relationships to disclose.

0.75 CEU/0.75 Hr
UAN: 0107-0000-26-156-H01-P
Initial release date: 5/4/2026
Expiration date: 5/4/2027
Additional CPE details can be found here.